<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="379">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522817</url>
  </required_header>
  <id_info>
    <org_study_id>CLBS119-P01</org_study_id>
    <nct_id>NCT04522817</nct_id>
  </id_info>
  <brief_title>CLBS119 for Repair of COVID-19 Induced Pulmonary Damage</brief_title>
  <official_title>CLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caladrius Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caladrius Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair
      of COVID-19 induced pulmonary damage in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label clinical trial will explore the safety and potential efficacy of peripheral
      blood derived autologous CD34+ cells for the repair of COVID-19 induced pulmonary damage in
      adults. Eligible subjects will receive a single administration of CLBS119.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through end of study (6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen saturation</measure>
    <time_frame>Change from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>CLBS119 Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of CLBS119</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLBS119</intervention_name>
    <description>Peripheral blood derived autologous CD34+ cells</description>
    <arm_group_label>CLBS119 Active Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Initial diagnosis with COVID-19 based on nasopharyngeal, oropharyngeal, or
             tracheobronchial aspirate SARS CoV-2 RT-PCR test

          -  Receiving or received ventilatory support for COVID-19 pneumonia/ARDS

          -  Evidence for ongoing pulmonary involvement based on P/F ratio &lt;300

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Immunocompromised or current use of immunosuppressive agents other than
             corticosteroids

          -  History of autoimmune disease

          -  Evidence of multiorgan failure

          -  Subject is pregnant or lactating at the time of signing the consent

          -  Participation in any other clinical trial of an experimental treatment for COVID-19

          -  History of sickle cell disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas W Losordo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Caladrius Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine L Kotynski</last_name>
    <phone>9084205753</phone>
    <email>ckotynski@caladrius.com</email>
  </overall_contact>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>COVID</keyword>
  <keyword>SARs-CoV-2</keyword>
  <keyword>Pulmonary Inflammation</keyword>
  <keyword>Respiratory Distress Syndrome</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Lung Injury</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Insufficiency</keyword>
  <keyword>ARDS</keyword>
  <keyword>pandemic</keyword>
  <keyword>Corona Virus Infection</keyword>
  <keyword>Coronavirus</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

